Q4 earnings beat for Moderna

February 25, 2022
Q4 earnings beat for Moderna

The drugmaker posted stronger-than-expected Q4 earnings. The company boosted the full-year sales forecast

Moderna posted diluted GAAP (generally accepted accounting principles) earnings per share of $11.29 for the three months ending in December. The figures are significantly higher than the 69 cents per share loss reported in the year-ago period. Group revenues also topped expectations, coming in at $7.21 billion. For the whole year, the company announced sales of $18.5 billion for 2021, significantly higher than the $803 million reported for 2020.

Moderna executives mentioned that they believe a fourth COVID-19 vaccine shot will be needed late this year due to waning protection from previous doses. This could push up sales in the second half of 2022. CEO Stephane Bancel stressed that Moderna’s current deals projections for Spikevax COVID-19 shot don’t include any additional sales in the US this year. The figures are expected to be at $19 billion in 2022. Orders for its vaccine have been confirmed for 2023 from Canada, the UK, and Taiwan.

Moderna’s stock price closed 15.10% higher, at $156.23 per share as of Thursday.

Sources: finance.yahoo.com, thestreet.com

This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.

Recently Added

Most Affected Instruments

Moderna Inc
moderna chart